Lilly's Foundayo: Game-Changer in Weight Loss Drug Market

Eli Lillys new oral weight loss pill, Foundayo, has seen remarkable success, with twenty thousand patients and eighty percent of them being new to GLP-one drugs. Lilly leads the U.S. market with sixty percent share, driven by superior weight loss results and strong revenue growth. The global demand for GLP-one meds is surging due to their ease of use and effectiveness. Lilly is expanding access and pipeline, setting the stage for further growth and making it an attractive opportunity for investors. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1d9cc3c21282005b